Doxorubicin-hydrazone-caproyl-maleimide is an albumin-binding prodrug of doxorubicin and a promising clinical candidate for the treatment of a broad range of solid tumors
the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (inno-206), formerly known as doxo-emch, is a prodrug of the anticancer agent doxorubicin which selectively binds to the cys34 of circulating albumin and accumulates in solid tumors due to passive targeting[1]. inno-206 shows significantly superior antitumor efficacy over free doxorubicin in a spectrum of preclinical tumor models [2].
in a murine renal cell carcinoma model and in breast carcinoma xenograft models, inno-206 has shown superior activity over doxorubicin. inno-206 has shown more potent antitumor efficacy than free doxorubicin in the tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors [2].
[1]. kratz f. doxo-emch (inno-206): the first albumin-binding prodrug of doxorubicin to enter
